Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

Group 1 - Intra-Cellular Therapies, Inc. announced the appointment of Sanjeev Narula as Executive Vice President and Chief Financial Officer, effective August 12, 2024 [1] - Lawrence Hineline, the current CFO, will retire on the same date but will remain as a consultant to ensure a smooth transition [1] - Dr. Sharon Mates, the CEO, expressed excitement about Mr. Narula's extensive experience in large commercial stage pharmaceutical companies, highlighting his strategic and operational expertise [2] Group 2 - Mr. Narula has significant experience in the pharmaceutical industry, having served as CFO of Viatris since its formation in 2020, and previously held various financial leadership roles at Pfizer [3] - His background includes overseeing finance, procurement, and business technology at Upjohn, and he has held positions at American Express and Xerox India [3] - Mr. Narula holds a bachelor's degree in commerce (honors) from Delhi University and is a Chartered Accountant [3] Group 3 - Mr. Narula expressed his honor in joining Intra-Cellular Therapies and his eagerness to contribute to the company's growth strategy, particularly in building on the commercial success of CAPLYTA and advancing its pipeline [4] - Intra-Cellular Therapies focuses on developing innovative treatments for complex psychiatric and neurologic diseases, based on Nobel prize-winning research [5]